Krishnendu Dey

Health

In a recent study published in the journal PNAS, researchers have formulated an intranasal vaccine called measles-mumps-SARS-CoV-2 spike (S) protein vaccine (MMS) that provides extensive and long-lasting safeguarding against prominent variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This innovative vaccine takes advantage of the well-established safety profile of the measles-mumps-rubella (MMR) vaccine platform.